个人简介
Jianqin Lu, BPharm, PhD, Assistant Professor of Pharmaceutical Sciences in Pharmaceutics and Pharmacokinetics, Department of Pharmacology and Toxicology.
The overarching goal of the Lu lab is to apply synthetic chemistry, nanoparticle engineering, and tumor immunology to develop efficacious nanotherapeutics to address the pressing unmet needs in current cancer therapy. The Lu Lab's expertise in Pharmaceutics, Drug Delivery, Nanomedicine and Tumor Immunology paves the way to develop transformative and clinically translatable nano-enabled immunotherapeutics for combatting cancers.
Post-Doctoral, Nanomedicine/Tumor Immunology, University of California, Los Angeles 2019
Post-Doctoral, Nanomedicine, The University of Chicago, 2015
PhD, Pharmaceutics, University of Pittsburgh, 2014
BS, Pharmacy, Hunan University of Chinese Medicine (China), 2010
研究领域
Drug Delivery
Nanomedicine
Pharmaceutics and Pharmacokinetics
Nano-ImmunoEngineering
Cancer Immunotherapy and Chemotherapy
Biomaterials
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
Wang Z, Chen J, Little N, Lu J. "Self-assembling Prodrug Nanotherapeutics for Synergistic Tumor Targeted Drug Delivery." Acta Biomater. 2020. PMCID: PMC7245299 PMID: 32454086
Lu J, Liu X, Liao Y-P, et al. "Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression." Nat Commun. 2017;8(1):1811. PMCID: PMC5703845 PMID: 29180759
Lu J, Liu C, Wang P, et al. "The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin." Biomaterials. 2015;62:176-87. PMCID: PMC4470812 PMID: 26057133
Lu J, Zhao W, Liu H, et al. "An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance." J Control Release. 2014;196:272-86. PMCID: PMC4267990 PMID: 25456831
Lu J, Huang Y, Zhao W, et al. "PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers." Biomaterials. 2013;34(5):1591-600. PMCID: PMC3529003 PMID: 23182923